Related to UPenn Alumni Gift $25M for Facility Focused on BRCA-Mutated Cancers

• Opinion: A Stem of Hope for Cancer Treatments
  Evidence mounts in favor of therapies targeting cancer stem cells.
  
• Customized Cancer Vaccines Finally (Maybe) Arrive
  Positive late-stage trial results are reinstating the potential of a personalized approach to treatment.
  
• GEN Exclusive: 2009 Laskers Honor Advances in Stem Cell Technology and Cancer Therapy
  Work cited will revolutionize cancer therapy and impact a potential $700 million global stem cell market.
  
• 2009 in Review: Headline-Making Stories in the Biotech Industry
  Even though last year was marred by the economic crash, the life science sector showed significant progress.
  
• Cancer Cell Line Identity Crisis
  Researchers weigh in on the impact of incorrectly labeled cell lines on cancer research and drug development.
  
• Roche Takes a Stab at Getting mAbs Under the Skin
  Firm is testing Herceptin SC in Phase III and expects to couple it with a user-friendly delivery device.
  
• Antibody-Drug Conjugates to Fight Cancer
  While mAbs have been extremely successful, these empowered antibodies are touted as the next big blockbusters.
  
• Avastin: Time for a Predictive Test
  Roche’s strategy to expand the use of Avastin into the first-line and adjuvant settings is particularly dependent on identifying those most likely to see a benefit.
  
• Nanotechnology Enables Precise Cancer Targeting
  While first-generation nanodrugs reduced toxicity, next-gen treatments are being designed to increase efficacy.
  
• What Comes After Dendreon’s Provenge?
  Success of prostate cancer vaccine has ushered in a wave of autologous vaccine development.